Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ellen Sher
Lebrikizumab is Efficacious in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Regardless of Atopic Comorbidities
1Allergy Partners of New Jersey, Ocean Township, and Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA 2Icahn School of Medicine at Mount Sinai, New York, New York, USA 3University Medical Center Utrecht, Utrecht, the Netherlands 4Hospital Universitario Germans Trias i Pujol, Universitat Autónoma de Barcelona, IGTP, Badalona, Spain 5Allergy & Asthma Associates of Southern California, Irvine, California, USA 6Christine Kühne-Center for Allergy Research and Education,...
Ellen Sher, MD: Cross-Specialty Collaboration Can Improve Atopic Dermatitis Management
The field of dermatology has found itself as the beneficiary of paradigm-shifting advances across a multitude of disease states in the last decade, with atopic dermatitis serving as a prime example of these new, pharmacotherapy-driven revolutions in care.
Lebrikizumab effective in moderate to severe atopic dermatitis through 52 weeks
You've successfully added Biologics/Immunotherapy to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: Percentages of patients with at least one atopic comorbidity ranged from 69.9% to 75.4%. Percentages of patients who maintained IGA scores of 0 or 1 ranged from 68% to 80% with treatment.
Efficacy of Lebrikizumab in Patients With Atopic Dermatitis and Atopic Comorbidities: Pooled Results From Two Phase 3 Monotherapy Randomized, Double-Blind, Placebo-Controlled 16-Week Studies (ADvocate1 and ADvocate2)
Atopic comorbidities are common in patients with atopic dermatitis (AD). We evaluated lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, in patients with AD with and without atopic comorbidities in 2 Phase 3, randomized, double-blind trials (ADvocate1 [NCT04146363] and ADvocate2 [NCT04178967]).
Post-hoc Analyses of Lebrikizumab Phase 3 Trials (LAVOLTA I and II): Enhanced Efficacy in Patients With Prior Exacerbations and Elevated Baseline FENO or Blood Eosinophilia
LAVOLTA I and II (LI&II) were duplicate placebo-controlled Phase 3 trials of lebrikizumab (LEB) in moderate-to-severe asthma that enrolled patients irrespective of asthma exacerbation history, baseline blood eosinophilia, or FENO. Two dose groups were studied: 125 mg and 37.5 mg Q4W. Primary endpoint was adjusted exacerbation rate ratio (AERR) in “Type 2 (T2) biomarker positive” patients (defined as periostin >50 ng/mL or blood eosinophils >300 cells/μL).
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ellen
Contact Ellen, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack